Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report

BACKGROUND: Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD). CASE PRESENTATION: A 53-year-old woman with HIV/hepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, José Ramón, Merino, Ana, Haefeli, Walter E., Miranda, Cristina, Prats, Marisol, Bancu, Ioana, Bailón, Lucía, Moltó, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988292/
https://www.ncbi.nlm.nih.gov/pubmed/31992232
http://dx.doi.org/10.1186/s12882-019-1659-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988292/
https://www.ncbi.nlm.nih.gov/pubmed/31992232
http://dx.doi.org/10.1186/s12882-019-1659-5

Ejemplares similares